Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Finance
Iclusig (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022

Global Iclusig market: Latest market research analysed


Print article Print article
© companiesandmarkets.com

companiesandmarkets.com
companiesandmarkets.com
2014-02-19 09:51:01 - Iclusig (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022 - a new market research report on companiesandmarkets.com

Iclusig (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022 - We have released our new PharmaPoint Drug Evaluation report, "Iclusig (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022". Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients´ survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare

 

 

systems.

Ariad´s Iclusig (ponatinib) is an orally administered, third-generation TKI that inhibits the activity of wild-type ABL and T315I mutant ABL in vitro. Iclusig has received orphan drug designation by the FDA and the EMA, and was granted accelerated approval by the FDA in December 2012 for the treatment of adults with CP, AP or BC CML and Ph+ ALL that is resistant or intolerant to prior TKI therapy. In Europe, the CHMP adopted a positive opinion on Iclusig, supporting marketing authorization; approval is expected by Q3 2013 (Ariad, press release, August 30, 2012).

Scope

- Overview of CML, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Iclusig including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Iclusig for the top seven countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for CML
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Iclusig performance
- Obtain sales forecast for Iclusig from 2012-2022 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..

Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..

About Us
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.com’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.


Author:
Mike King
e-mail
Web: www.companiesandmarkets.com
Phone: London: +44 (0) 203 086 8600

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com | BidVertiser